![Safety profile of MyeloVec. (A) IVIM assay displaying the replating frequency (RF) of MyeloVec and CCLchim-gp91phox-WPRE and control samples (Mock and RSF91). Data are compared with a meta-analysis (MA) for control samples (MA-Mock, MA-RSF91, MA-LV-SF). Above the graph, the incidence of positive (RF >3.17 × 10−4) and negative plates (RF <3.17 × 10−4) according to the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay are shown. (B) SAGA assay displaying gene expression analysis. A positive NES indicates an upregulation of oncogenic core set genes. Data are compared with a MA of a positive control (MARSF91) or SIN LV with an internal EFS promoter (MA-LV.EFS). Plates with no wells above the MTT threshold. Bars indicate means. Difference in the incidence of positive and negative IVIM assays relative to Mock-MA or RSF91-MA were analyzed by Fisher exact test with Benjamini-Hochberg correction. Statistical comparison with MA-RSF-91 in SAGA was analyzed by Kruskal-Wallis with Dunn correction; ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001. RSF91, mutagenic gammaretroviral vector with enhancer/promoter of spleen focus–forming virus in both LTRs; LV-SF, self-inactivating LV under control of the spleen focus–forming virus internal promoter; EFS, self-inactivating LV under control of the shorten promoter of the EEF1A1 gene; LOD, limitation of detection.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/141/9/10.1182_blood.2022016074/2/blood_bld-2022-016074-gr7.jpeg?Expires=1720560761&Signature=lB~goAo24e2SfJQE4CIzwB7CvtrGijKwlsTHfQqHDwhdr7Q7OGSzO5aQ~gtk2B04dZ2XnGXwofliBSf-SRhQejwgBBpvNK7HLSPTtp1aH7YIOE-uDsCwWk2fYgLVohJIMaZjZDQYVhNKhC0YStGpZcX0g9NZattvn-vkcr15cXDXzf~e4x12L9RRWHhQmlQ6mgXMAdZp99DutmTe5NECT~zCWq9Wutiev-g58FFh7RiTjxiKrdrpuY7OjJDkU9Rh7b1NEBpwyTOyNySeRWe7--FtI2Y8DH2V~TYSn8OVkfZr-ji0iduKr6av3UeH9rs7jMROtpZP-TS3JsCqwgHJow__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Safety profile of MyeloVec. (A) IVIM assay displaying the replating frequency (RF) of MyeloVec and CCLchim-gp91phox-WPRE and control samples (Mock and RSF91). Data are compared with a meta-analysis (MA) for control samples (MA-Mock, MA-RSF91, MA-LV-SF). Above the graph, the incidence of positive (RF >3.17 × 10−4) and negative plates (RF <3.17 × 10−4) according to the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay are shown. (B) SAGA assay displaying gene expression analysis. A positive NES indicates an upregulation of oncogenic core set genes. Data are compared with a MA of a positive control (MARSF91) or SIN LV with an internal EFS promoter (MA-LV.EFS). Plates with no wells above the MTT threshold. Bars indicate means. Difference in the incidence of positive and negative IVIM assays relative to Mock-MA or RSF91-MA were analyzed by Fisher exact test with Benjamini-Hochberg correction. Statistical comparison with MA-RSF-91 in SAGA was analyzed by Kruskal-Wallis with Dunn correction; ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001. RSF91, mutagenic gammaretroviral vector with enhancer/promoter of spleen focus–forming virus in both LTRs; LV-SF, self-inactivating LV under control of the spleen focus–forming virus internal promoter; EFS, self-inactivating LV under control of the shorten promoter of the EEF1A1 gene; LOD, limitation of detection.
